Oraya Therapeutics Publishes Results of Wet AMD Treatment Study

Oraya Therapeutics, Newark, Calif.-based minimally invasive ophthalmic treatment company, has published the results of a study analyzing the effectiveness and safety of its wet age-related macular degeneration therapy in Ophthalmology.

Advertisement

The INTREPID study demonstrated that Oraya Therapy Stereotactic Radiotherapy decreased the amount of anti-VEGF injections needed to treat macular degeneration patients.

More Articles on Ophthalmology:
3 Statistics on Cataract Surgery Procedure Times in ASCs
Abbott Medical Optics Appoints Dr. David Tanzer Chief Medical Officer
Hubble Telemedical Launches EyeQ Wellness Exam

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.